Acta Pharmaceutica Sinica B (Mar 2019)

Biosynthesis of clinically used antibiotic fusidic acid and identification of two short-chain dehydrogenase/reductases with converse stereoselectivity

  • Zhiqin Cao,
  • Shaoyang Li,
  • Jianming Lv,
  • Hao Gao,
  • Guodong Chen,
  • Takayoshi Awakawa,
  • Ikuro Abe,
  • Xinsheng Yao,
  • Dan Hu

Journal volume & issue
Vol. 9, no. 2
pp. 433 – 442

Abstract

Read online

Fusidic acid is the only fusidane-type antibiotic that has been clinically used. However, biosynthesis of this important molecule in fungi is poorly understood. We have recently elucidated the biosynthesis of fusidane-type antibiotic helvolic acid, which provides us with clues to identify a possible gene cluster for fusidic acid (fus cluster). This gene cluster consists of eight genes, among which six are conserved in the helvolic acid gene cluster except fusC1 and fusB1. Introduction of the two genes into the Aspergillus oryzae NSAR1 expressing the conserved six genes led to the production of fusidic acid. A stepwise introduction of fusC1 and fusB1 revealed that the two genes worked independently without a strict reaction order. Notably, we identified two short-chain dehydrogenase/reductase genes fusC1 and fusC2 in the fus cluster, which showed converse stereoselectivity in 3-ketoreduction. This is the first report on the biosynthesis and heterologous expression of fusidic acid. KEY WORDS: Biosynthesis, Fungi, Fusidic acid, Fusidane-type antibiotics, SDR